Inmed pharmaceuticals provides business update and milestones for 2024

Advancing inm-901 as a multimodal treatment option for alzheimer's disease advancing inm-089 in the treatment of age-related macular degeneration actively seeking partnerships to advance inm-755 in dermatology baymedica subsidiary continues to focus on revenue growth and market expansion vancouver, british columbia--(newsfile corp. - january 16, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlines key accomplishments from 2023 and provides key strategic priorities for 2024. eric a. adams, inmed president and ceo, commented, "in 2023, we experienced significant progress in both inmed's pharmaceutical drug development and in baymedica's health and wellness initiatives.
INM Ratings Summary
INM Quant Ranking